Sampling of dermal Interstitial Fluid (dISF)

Pioneering Hollow Microneedles

Ascilion designs, develops, and manufactures products based on hollow microneedles for sampling of dermal interstitial fluid (dISF).
Access to endogenous and exogeneous biomolecules in dISF represents a unique opportunity for analysis of vital markers, health conditions and for research.
Bringing biomolecules out of the body and into analysis is paramount for the next step in life science.
Contact us


Founded on the premise of radically improving healthcare, the team set out to develop hollow microneedles that can sample dermal interstitial fluid in a pain-free and easy to use way. After almost 10 years of development, the company is entering into numerous clinical trials with the aim of characterizing both the system and dISF itself.
Read more

The needle chip

Etched from pure silicon using MEMS technology, the needle chip is the core in Ascilion’s sampling products.
Patent Families


March 25, 2024
Dermal ISF sampling abstract presented by Charité and Fraunhofer at the 2024 ADF meeting in Germany

For the third time Ascilion’s dermal ISF sampling solutions were presented at the annual meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) in Germany.

This year, researchers from the Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Allergology and Immunology, Berlin, and Institute of Allergology (IA), Charité - Universitätsmedizin Berlin, presented the application of Ascilion’s hollow microneedles in a model of chronic inducible urticaria. 

Read the abstract (on page 7):P014 - 15.1 “Application of hollow microneedles in a model of chronic inducible urticaria” (Shi et al. 2024)

Ascilion ADF abstracts from 2024 and previous years can be found here: ADF Abstract Books 

October 13, 2023
Ascilion to exhibit at the Dermatology Drug Development Summit for Inflammatory Skin Diseases in Boston

Ascilion will attend and exhibit at the 7th Annual Dermatology Drug Development Summit for Inflammatory Skin Disease in Boston. The meeting will be held from the 31st October - 2nd November 2023

The conference is specifically for executives from pharmaceutical companies working within drug development in the inflammatory skin disease area. This will be an excellent opportunity for Ascilion to discuss how it's dermal interstitial fluid (dISF) sampling technology can assist pharma companies in their development processes.

For more information on the conference:

October 3
Ascilion appoints Simon Grant as Chief Executive Officer

STOCKHOLM, SWEDEN, October 3, 2023 / -- Ascilion AB ("Ascilion") the world leader in interstitial fluid (ISF) sampling for biomarker investigation announced yesterday that the Board has appointed Simon Grant as Chief Executive Officer (CEO).

Simon has extensive Life Science industry experience, having held management positions in smaller startups such as Neoventa and Synectics Medical, and large multinationals such as Medtronic and Sandvik. Most recently Simon held the position of CEO at SciBase AB, a Swedish point-of-care diagnostics company listed on Nasdaq First North, Stockholm.

Sten Dahlborg, Chairman of the Board at Ascilion commented: "We are very happy to welcome Simon as CEO, and his appointment signals a new phase in the development of Ascilion. Simon brings extensive commercialization experience, having developed and introduced more than a dozen new medical technologies in the international market. His enthusiasm towards our technology and its application reinforces our belief in its potential" Furthermore, he added: "I would also like to take the opportunity to thank Markus Renlund for the excellent work he has done to lead the company to this stage. Markus will continue with the Company, both as a Board member and in his role as Technology and Innovation Lead.

Simon Grant commented "In my opinion interstitial fluid sampling has the potential to disrupt the standard of care in multiple clinical specialties and drive significant research and wellness applications. ISF contains a ‘treasure trove’ of biomarker information that until now has been mostly untapped because it is practically so difficult to extract. Ascilion is a world leader in hollow microneedles, and it is that technology that enables us to access ISF in useful volumes for the very first time. I believe that Ascilion has the ability to change the way that things are done clinically and that we can build a significant business around the technology – and this is especially exciting for me.”

For further information visit or contact:

Sten Dahlborg, Chairman

Tel: +46 70 836 94 19


Simon Grant, CEO

Tel: +46 72 887 43 99


About Ascilion

Ascilion is the world leader in sampling of dermal interstitial fluid (dISF). A pioneer within hollow microneedle technology since 2012, Ascilion has developed the only solution available for sampling of practical amounts of pure dISF, enabling complete quantitative biomarker evaluation. Ascilion’s technology is painless, quick, easy to use and leaves no residual mark on the skin. Products are available for research use and for pharmaceutical or cosmetic testing applications and are currently undergoing the medical product approval process. We are a cross-functional team based just outside Stockholm, Sweden working closely with industry-leading customers in several target segments.

More news

The core technology

Ascilion’s core technology utilizes 3D processing of silicon on wafer scale with world leading expertise in MEMS design (Micro-Electro-Mechanical-Systems) and productization of semiconductor components and systems.
Read more
User Friendly
The system and method enable user friendly sampling of dermal interstitial fluid.
The sampling experience can be likened to gently touching Velcro.
Multiple hollow microneedles sample on average one microliter of dermal interstitial fluid per minute, adequate volumes for modern analysis equipment in a short time span.
Easy to use
We have designed a complete sampling system around a MEMS chip containing over 100 hollow microneedles.

Get in touch

Contact us

Get in touch

Contact us

Join our team

Contact us